Skip to content
Screener

Axsome Therapeutics AXSM Amortization of capitalized software and acquired intangible assets

Amortization of capitalized software and acquired intangible assets at other companies

Alkermes logo
AlkermesALKS

Other financials

Income statement

See full
Revenue$218.4M+45.5%
Gross profit$204.8M+49.9%
Operating income-$49.6M-35.2%
Net income-$51.3M-7.0%
EPS (diluted)-$0.99-2.1%

Balance sheet

See full
Cash & equivalents$319.9M+5.6%
Total debt$224.7M+3.4%
Total equity$83.3M+14.0%
Total assets$761.4M+19.0%

Cash flow

See full
Operating cash flow-$33.0M-1.6%
CapEx$450.0K+3,362%
Free cash flow-$33.4M-3.0%

Valuation

See full
Market cap$11.37B+119%
Enterprise value$11.27B+121%
P/S14.6×+4.2×

Profitability

See full
Gross margin93.2%+1.8pp
Operating margin-24%-7.8pp
Net margin-24.7%-8.3pp
FCF margin-9.4%-3.6pp

Returns & leverage

See full
Return on equity-245.1%-27.6pp
Debt / equity2.7×-0.3×
Current ratio1.4×-0.1×

Where this comes from

Reported directly by Axsome Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The source filing: Axsome Therapeutics’s 10-Q, filed August 10, 2026.

Filed
Aug 10, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-342360
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Research and development46,22749,54198,90494,326
Selling, general and administrative208,137130,280393,133251,067
Gain in fair value of contingent consideration(1,496)(8,102)(906)(6,590)
Intangible asset amortization1,5891,5893,1613,161
Total operating expenses268,021186,756522,581365,201
Loss from operations(49,646)(36,714)(113,003)(93,696)
Interest expense, net(1,540)(1,834)(2,725)(4,265)
Loss on debt extinguishment(10,385)(10,385)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Axsome Therapeutics's amortization of capitalized software and acquired intangible assets?
Axsome Therapeutics (AXSM) reported amortization of capitalized software and acquired intangible assets of $1.59M in Q2 2026.
How has Axsome Therapeutics's amortization of capitalized software and acquired intangible assets changed year-over-year?
Axsome Therapeutics's amortization of capitalized software and acquired intangible assets decreased by 0.0% year-over-year, from $1.59M to $1.59M.
What is the long-term trend for Axsome Therapeutics's amortization of capitalized software and acquired intangible assets?
Over 3 years (2022 to 2025), Axsome Therapeutics's amortization of capitalized software and acquired intangible assets has grown at a 15.5% compound annual growth rate (CAGR), from $4.14M to $6.38M.
What does amortization of capitalized software and acquired intangible assets mean?
Amortization of capitalized software and acquired intangible assets

Ask your AI about Axsome Therapeutics's amortization of capitalized software and acquired intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude